Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Raised by XTX Topco Ltd

XTX Topco Ltd grew its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 751.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 364,681 shares of the biopharmaceutical company’s stock after buying an additional 321,859 shares during the period. XTX Topco Ltd owned 0.19% of Esperion Therapeutics worth $810,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ESPR. BOKF NA bought a new stake in Esperion Therapeutics during the second quarter worth approximately $26,000. CVI Holdings LLC acquired a new position in Esperion Therapeutics in the first quarter worth approximately $37,000. Sivia Capital Partners LLC acquired a new position in Esperion Therapeutics in the second quarter worth approximately $44,000. National Bank of Canada FI grew its position in Esperion Therapeutics by 115.9% in the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 10,225 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new position in Esperion Therapeutics in the first quarter worth approximately $50,000. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Stock Performance

NASDAQ ESPR opened at $1.68 on Monday. Esperion Therapeutics, Inc. has a twelve month low of $0.70 and a twelve month high of $3.40. The stock has a market cap of $318.29 million, a price-to-earnings ratio of -1.70 and a beta of 1.00. The firm’s 50 day moving average price is $1.99 and its two-hundred day moving average price is $2.22.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The company had revenue of $73.83 million during the quarter, compared to analyst estimates of $51.90 million. On average, research analysts forecast that Esperion Therapeutics, Inc. will post -0.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on ESPR. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Monday, August 12th. Needham & Company LLC decreased their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. StockNews.com upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Bank of America cut shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price objective for the stock from $2.90 to $2.50 in a research report on Thursday, June 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.17.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.